Entera Bio Ltd. (ENTX)
ENTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.49
-6.04% on the day
Market cap
$433.1M
Small cap
Revenue · 2025
$42K
-76.8% on 2024
Net income · 2025
-$11.4M
-27235.7% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ENTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Israel |
| IPO year | 2018 |
| SEC CIK | 0001638097 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | L3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $42K |
| Net income | -$11.4M |
| Operating income | -$11.5M |
| Net margin | -27235.7% |
| Operating margin | -27450.0% |
| Revenue growth | -76.8% |
| Cash | $7.1M |
| Total assets | $16.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 10311.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-28 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-08-07 |
| Latest current report | 8-K | 2026-10-06 |
| Latest proxy | DEF 14A | 2026-10-14 |
Source: SEC EDGAR submissions feed, 416 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.8% |
| 1 month | -12.9% |
| 3 months | +24.5% |
| Year to date | +28.4% |
| 1 year | -7.8% |
| From 52-week high | -36.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AGMB | AgomAb Therapeutics NV | $8.81 | -3.08% | $433.9M |
| AUTL | Autolus Therapeutics plc American Depositary Share | $1.62 | -6.90% | $431.2M |
| ALLO | Allogene Therapeutics Inc. | $1.29 | -7.86% | $445.7M |
| TECX | Tectonic Therapeutic Inc. | $21.31 | -4.65% | $416.6M |
| ZURA | Zura Bio Limited | $4.23 | +5.75% | $405.4M |
| PROK | ProKidney Corp. | $1.57 | -5.99% | $474.6M |
| RGNX | REGENXBIO Inc. | $7.26 | -6.56% | $479.3M |
| EDIT | Editas Medicine Inc. | $2.44 | -11.09% | $375.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier